Kidney Regeneration in Mammals

Overview

Journal Nephron Exp Nephrol

Publisher Karger

Specialties Biology
Nephrology

Date 2014 May 24

PMID 24854640

Citations 6

Authors

Hai-Chun Yang

Shao-Jun Liu

Agnes B Fogo

Affiliations

Soon will be listed here.

Abstract

Background: Several organs such as the skin and liver have a great capacity for regeneration. However, many approaches only delay the progression of end-stage kidney disease and do not achieve efficient long-term stabilization, let alone regeneration.

Summary: In mammals, the kidney has an innate but limited capacity for regeneration which can only modify the nephron structure and function but not increase the nephron number. Several clinical and animal studies have indicated that functional improvements and/or structural regression can occur in chronic kidney disease. Cell reconstitution, matrix remodeling, and tissue reorganization are major mechanisms for kidney regeneration. Current approaches achieve only partial kidney regeneration, but this does not occur in all animals and is not sustained in the long term. Multipronged and early interventions are future choices for the induction of kidney regeneration.

Key Messages: Kidney regeneration in mammals is feasible but limited and may be enhanced by multitargeting key mechanisms.

Citing Articles

Retina regeneration: lessons from vertebrates.

Sharma P, Ramachandran R Oxf Open Neurosci. 2024; 1:kvac012.

PMID: 38596712 PMC: 10913848. DOI: 10.1093/oons/kvac012.

Kidney Injury: Focus on Molecular Signaling Pathways.

Liu W, Hu M, Wang L, Mirzaei H Curr Med Chem. 2024; 31(28):4510-4533.

PMID: 38314680 DOI: 10.2174/0109298673271547231108060805.

Single-cell profiling of vascular endothelial cells reveals progressive organ-specific vulnerabilities during obesity.

Bondareva O, Rodriguez-Aguilera J, Oliveira F, Liao L, Rose A, Gupta A Nat Metab. 2022; 4(11):1591-1610.

PMID: 36400935 PMC: 9684070. DOI: 10.1038/s42255-022-00674-x.

Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Lv W, Fan F, Wang Y, Gonzalez-Fernandez E, Wang C, Yang L Physiol Genomics. 2017; 50(1):20-34.

PMID: 29127220 PMC: 5866411. DOI: 10.1152/physiolgenomics.00039.2017.

IL-36α Regulates Tubulointerstitial Inflammation in the Mouse Kidney.

Ichii O, Kimura J, Okamura T, Horino T, Nakamura T, Sasaki H Front Immunol. 2017; 8:1346.

PMID: 29109726 PMC: 5660075. DOI: 10.3389/fimmu.2017.01346.

References

Adamczak M, Gross M, Amann K, Ritz E . Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol. 2004; 15(12):3063-72. DOI: 10.1097/01.ASN.0000146121.72699.86. View

Combs H, Shankland S, Setzer S, Hudkins K, Alpers C . Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int. 1998; 53(4):892-6. DOI: 10.1111/j.1523-1755.1998.00842.x. View

Aldigier J, Kanjanbuch T, Ma L, Brown N, Fogo A . Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005; 16(11):3306-14. DOI: 10.1681/ASN.2004090804. View

Pichaiwong W, Hudkins K, Wietecha T, Nguyen T, Tachaudomdach C, Li W . Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol. 2013; 24(7):1088-102. PMC: 3699819. DOI: 10.1681/ASN.2012050445. View

Scruggs B, Zuo Y, Donnert E, Ma L, Bertram J, Fogo A . Increased capillary branching contributes to angiotensin type 1 receptor blocker (ARB)-induced regression of sclerosis. Am J Pathol. 2011; 178(4):1891-8. PMC: 3078453. DOI: 10.1016/j.ajpath.2010.12.029. View

Liang X, Ma L, Naito T, Wang Y, Madaio M, Zent R . Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 2006; 17(7):1886-95. DOI: 10.1681/ASN.2005020205. View

Macconi D, Sangalli F, Bonomelli M, Conti S, Condorelli L, Gagliardini E . Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol. 2009; 174(3):797-807. PMC: 2665741. DOI: 10.2353/ajpath.2009.080227. View

Nemeth Z, Kokeny G, Godo M, Mozes M, Rosivall L, Gross M . Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes. Nephrol Dial Transplant. 2009; 24(12):3640-51. DOI: 10.1093/ndt/gfp371. View

Ma L, Nakamura S, Aldigier J, Rossini M, Yang H, Liang X . Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005; 16(4):966-76. DOI: 10.1681/ASN.2004060492. View

10.

Marinides G, Groggel G, Cohen A, Border W . Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int. 1990; 37(2):749-57. DOI: 10.1038/ki.1990.42. View

11.

Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C . How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002; 13(12):2898-908. DOI: 10.1097/01.asn.0000034912.55186.ec. View

12.

Fioretto P, Steffes M, Sutherland D, Goetz F, Mauer M . Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998; 339(2):69-75. DOI: 10.1056/NEJM199807093390202. View

13.

Xu B, Shyr Y, Liang X, Ma L, Donnert E, Roberts J . Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol. 2005; 16(10):2967-75. DOI: 10.1681/ASN.2005030262. View

14.

Adamczak M, Gross M, Krtil J, Koch A, Tyralla K, Amann K . Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol. 2003; 14(11):2833-42. DOI: 10.1097/01.asn.0000095248.91994.d3. View

15.

Kang D, Hughes J, Mazzali M, Schreiner G, Johnson R . Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001; 12(7):1448-1457. DOI: 10.1681/ASN.V1271448. View

16.

Wilmer W, Hebert L, Lewis E, Rohde R, Whittier F, Cattran D . Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis. 1999; 34(2):308-14. DOI: 10.1016/s0272-6386(99)70360-4. View

17.

Fioretto P, Sutherland D, Najafian B, Mauer M . Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int. 2006; 69(5):907-12. DOI: 10.1038/sj.ki.5000153. View

18.

Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, MAGGIORE Q . In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol. 1999; 10(5):997-1006. DOI: 10.1681/ASN.V105997. View

19.

Fogo A . Progression and potential regression of glomerulosclerosis. Kidney Int. 2001; 59(2):804-19. DOI: 10.1046/j.1523-1755.2001.059002804.x. View

20.

Boffa J, Lu Y, Placier S, Stefanski A, Dussaule J, Chatziantoniou C . Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003; 14(5):1132-44. DOI: 10.1097/01.asn.0000060574.38107.3b. View